Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome

Background: The UK National Health Service (NHS) propose the use of oxybutynin prior to onabotulinumtoxinA (Botox) in the management of overactive bladder syndrome (OAB). Oxybutynin is costly and associated with poor adherence, which may not occur with Botox. We conducted a cost-utility analysis (CU...

Descripción completa

Detalles Bibliográficos
Autores principales: Shabir, Habiba, Hashemi, Sana, Al-Rufayie, Moussa, Adelowo, Tayo, Riaz, Umar, Ullah, Umayair, Alam, Benyamin, Anwar, Mehreen, de Preux, Laure
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394450/
https://www.ncbi.nlm.nih.gov/pubmed/34444493
http://dx.doi.org/10.3390/ijerph18168743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394450/
https://www.ncbi.nlm.nih.gov/pubmed/34444493
http://dx.doi.org/10.3390/ijerph18168743

Ejemplares similares